AU2016349707B2 - Compositions comprising an inhibitor of lysine specific demethylase-1 - Google Patents
Compositions comprising an inhibitor of lysine specific demethylase-1 Download PDFInfo
- Publication number
- AU2016349707B2 AU2016349707B2 AU2016349707A AU2016349707A AU2016349707B2 AU 2016349707 B2 AU2016349707 B2 AU 2016349707B2 AU 2016349707 A AU2016349707 A AU 2016349707A AU 2016349707 A AU2016349707 A AU 2016349707A AU 2016349707 B2 AU2016349707 B2 AU 2016349707B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- fluoro
- oxo
- piperidin
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562251507P | 2015-11-05 | 2015-11-05 | |
| US62/251,507 | 2015-11-05 | ||
| PCT/US2016/060694 WO2017079670A1 (en) | 2015-11-05 | 2016-11-04 | Compositions comprising an inhibitor of lysine specific demethylase-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016349707A1 AU2016349707A1 (en) | 2018-05-24 |
| AU2016349707B2 true AU2016349707B2 (en) | 2020-12-10 |
Family
ID=58662888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016349707A Active AU2016349707B2 (en) | 2015-11-05 | 2016-11-04 | Compositions comprising an inhibitor of lysine specific demethylase-1 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9828358B2 (es) |
| EP (1) | EP3371152B1 (es) |
| JP (1) | JP6995043B2 (es) |
| CN (1) | CN108473442B (es) |
| AR (1) | AR106612A1 (es) |
| AU (1) | AU2016349707B2 (es) |
| CA (1) | CA3004300C (es) |
| CY (1) | CY1124078T1 (es) |
| DK (1) | DK3371152T3 (es) |
| ES (1) | ES2846951T3 (es) |
| HR (1) | HRP20210144T8 (es) |
| HU (1) | HUE053449T2 (es) |
| LT (1) | LT3371152T (es) |
| MX (2) | MX2020004894A (es) |
| PL (1) | PL3371152T3 (es) |
| PT (1) | PT3371152T (es) |
| RS (1) | RS61404B1 (es) |
| SI (1) | SI3371152T1 (es) |
| TW (1) | TW201720808A (es) |
| WO (1) | WO2017079670A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3137169T1 (sl) | 2014-05-01 | 2022-04-29 | Celgene Quanticel Research, Inc. | Inhibitorji lizin specifične demetilaze-1 |
| CN108473442B (zh) * | 2015-11-05 | 2022-03-25 | 赛尔基因昆蒂赛尔研究公司 | 包含赖氨酸特异性脱甲基酶-1的抑制剂的组合物 |
| EP3535420A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| US20200069677A1 (en) | 2016-12-09 | 2020-03-05 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
| EP3661510B1 (en) | 2017-08-03 | 2024-10-09 | Oryzon Genomics, S.A. | Methods of treating behavior alterations |
| WO2020188089A1 (en) | 2019-03-20 | 2020-09-24 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| BR112021016064A2 (pt) | 2019-03-20 | 2021-10-05 | Oryzon Genomics, S.A. | Métodos de tratamento do transtorno de personalidade borderline |
| EP3983016A4 (en) * | 2019-06-13 | 2023-06-07 | Celgene Corporation | METHODS OF TREATMENT OF CANCER BY TARGETING COLD TUMORS |
| EP3986403A1 (en) * | 2019-06-20 | 2022-04-27 | Celgene Corporation | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
| WO2021004610A1 (en) | 2019-07-05 | 2021-01-14 | Oryzon Genomics, S.A. | Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors |
| CN116056707A (zh) * | 2020-06-05 | 2023-05-02 | 赛尔基因昆蒂赛尔研究公司 | 治疗前列腺癌的方法 |
| ES2919083R1 (es) * | 2020-06-29 | 2022-07-26 | Celgene Quanticel Res Inc | Métodos de tratamiento de cáncer de próstata |
| TW202304416A (zh) | 2021-04-08 | 2023-02-01 | 西班牙商奧萊松基因組股份有限公司 | 用於治療骨髓癌的ｌｓｄ１抑制劑的組合 |
| WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| WO2023217784A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| WO2024110649A1 (en) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015107493A1 (en) * | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| CA2513414A1 (en) * | 2002-04-10 | 2003-10-16 | Orchid Chemicals & Pharmaceuticals Limited | Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases |
| WO2003084936A2 (en) | 2002-04-10 | 2003-10-16 | Orchid Chemicals & Pharmaceuticals Limited | Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological |
| JP2008515902A (ja) | 2004-10-06 | 2008-05-15 | エヌピーエス ファーマシューティカルズ インコーポレイテッド | カルシウム拮抗化合物としての相補ピリミジノン化合物 |
| AR073760A1 (es) * | 2008-10-03 | 2010-12-01 | Astrazeneca Ab | Derivados heterociclicos y metodos de uso de los mismos |
| SI3137169T1 (sl) * | 2014-05-01 | 2022-04-29 | Celgene Quanticel Research, Inc. | Inhibitorji lizin specifične demetilaze-1 |
| CN108473442B (zh) * | 2015-11-05 | 2022-03-25 | 赛尔基因昆蒂赛尔研究公司 | 包含赖氨酸特异性脱甲基酶-1的抑制剂的组合物 |
-
2016
- 2016-11-04 CN CN201680076854.5A patent/CN108473442B/zh active Active
- 2016-11-04 HU HUE16863111A patent/HUE053449T2/hu unknown
- 2016-11-04 CA CA3004300A patent/CA3004300C/en active Active
- 2016-11-04 JP JP2018522953A patent/JP6995043B2/ja active Active
- 2016-11-04 DK DK16863111.7T patent/DK3371152T3/da active
- 2016-11-04 WO PCT/US2016/060694 patent/WO2017079670A1/en active Application Filing
- 2016-11-04 RS RS20210094A patent/RS61404B1/sr unknown
- 2016-11-04 SI SI201631055T patent/SI3371152T1/sl unknown
- 2016-11-04 EP EP16863111.7A patent/EP3371152B1/en active Active
- 2016-11-04 AU AU2016349707A patent/AU2016349707B2/en active Active
- 2016-11-04 ES ES16863111T patent/ES2846951T3/es active Active
- 2016-11-04 LT LTEP16863111.7T patent/LT3371152T/lt unknown
- 2016-11-04 PL PL16863111T patent/PL3371152T3/pl unknown
- 2016-11-04 PT PT168631117T patent/PT3371152T/pt unknown
- 2016-11-04 MX MX2020004894A patent/MX2020004894A/es unknown
- 2016-11-04 MX MX2018005620A patent/MX2018005620A/es active IP Right Grant
- 2016-11-04 US US15/344,426 patent/US9828358B2/en active Active
- 2016-11-07 TW TW105136105A patent/TW201720808A/zh unknown
- 2016-11-07 AR ARP160103391A patent/AR106612A1/es unknown
-
2017
- 2017-10-25 US US15/793,512 patent/US10047069B2/en active Active
-
2018
- 2018-07-10 US US16/032,002 patent/US10316016B2/en active Active
-
2019
- 2019-06-10 US US16/436,541 patent/US10703739B2/en active Active
-
2021
- 2021-01-27 HR HRP20210144TT patent/HRP20210144T8/hr unknown
- 2021-01-28 CY CY20211100072T patent/CY1124078T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015107493A1 (en) * | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016349707B2 (en) | Compositions comprising an inhibitor of lysine specific demethylase-1 | |
| US11773068B2 (en) | KDM1A inhibitors for the treatment of disease | |
| IL259738A (en) | Crystalline forms of the androgen receptor modulator | |
| US20230120311A1 (en) | Salts and crystalline forms of a taar1 agonist | |
| JP2015522037A (ja) | ベムラフェニブコリン塩の固体形態 | |
| BR102015025502B1 (pt) | Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição | |
| JP2023524622A (ja) | ６－クロロ－７－（４－（４－クロロベンジル）ピペラジン－１－イル）－２－（１，３－ジメチル－１Ｈ－ピラゾール－４－イル）－３Ｈ－イミダゾ［４，５－ｂ］ピリジンの塩及び多形体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |